IFNG and neoplasm: In the context of the same in vitro model, the pre-treatment of CRC-CSCs/CICs with immunomodulatory agents (IFN-γ) could increase the antigen processing and presentation of these cells and induce antigen-specific immune responses against a neoantigen generated by a non-synonymous mutation detected both in tumor cells with stemness properties and in the bulk tumor cells [103].